Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341209 · ClinicalTrials.gov registry record · Phase 2
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by Rochester General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02341209: Clinical Trial Phase 2 study, sponsored by Rochester General Hospital.
NCT02341209 is a Phase 2 study that was terminated before completion, run by Rochester General Hospital. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02341209, a Phase 2 study, was terminated before completion, sponsored by Rochester General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
Primary Outcome
Overall response rate will be determined after five months or a year from initiation of therapy.
Interventions
- DRUG Doxycycline monohydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2021-02-06 |
| Phase | Phase 2 |
Why NCT02341209 stopped before completion
NCT02341209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Doxycycline monohydrate is the first listed.
NCT02341209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02341209 about?
NCT02341209 is a clinical study titled "Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma". This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.
What is the current status of trial NCT02341209?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2018-02-06. Estimated completion is 2021-02-06.
What interventions are being tested in trial NCT02341209?
The interventions under investigation include: Doxycycline monohydrate (DRUG).
Who is sponsoring clinical trial NCT02341209?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02341209's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI